tamoxifen ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2561 10540-29-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tamoxifen
  • tamoxifen citrate
  • tamoxifene
  • tamoxifene citrate
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
  • Molecular weight: 371.52
  • Formula: C26H29NO
  • CLOGP: 6.82
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 12.47
  • ALOGS: -5.56
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.18 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1977 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metastases to bone 1434.74 11.37 517 33872 17478 50553257
Malignant neoplasm progression 1369.95 11.37 742 33647 67382 50503353
Metastases to liver 793.98 11.37 348 34041 19756 50550979
Metastases to lung 474.91 11.37 203 34186 10817 50559918
Metastases to lymph nodes 428.28 11.37 166 34223 6858 50563877
Breast cancer recurrent 389.86 11.37 132 34257 3676 50567059
Disease progression 369.21 11.37 387 34002 95479 50475256
Breast cancer metastatic 362.80 11.37 165 34224 10199 50560536
Neoplasm progression 342.12 11.37 225 34164 28932 50541803
Osteonecrosis of jaw 232.68 11.37 186 34203 32340 50538395
Breast cancer 205.18 11.37 195 34194 42695 50528040
Metastasis 183.17 11.37 79 34310 4296 50566439
Uterine polyp 160.39 11.37 56 34333 1712 50569023
Metastases to central nervous system 159.50 11.37 98 34291 11184 50559551
Metastases to spine 144.94 11.37 59 34330 2772 50567963
Hot flush 143.08 11.37 163 34226 44006 50526729
Endometrial hyperplasia 139.86 11.37 41 34348 701 50570034
Osteonecrosis 136.46 11.37 117 34272 22400 50548335
Bone disorder 133.55 11.37 107 34282 18645 50552090
Second primary malignancy 129.28 11.37 72 34317 6842 50563893
PIK3CA-activated mutation 119.26 11.37 37 34352 773 50569962
Bone lesion 113.83 11.37 60 34329 5110 50565625
Hormone receptor positive breast cancer 110.14 11.37 31 34358 455 50570280
Acute myeloid leukaemia 109.44 11.37 87 34302 14987 50555748
Drug ineffective 106.38 11.37 252 34137 819081 49751654
Sarcoma uterus 101.35 11.37 18 34371 17 50570718
Tumour marker increased 100.29 11.37 50 34339 3790 50566945
Endometrial hypertrophy 97.33 11.37 25 34364 253 50570482
Metastases to pleura 94.52 11.37 35 34354 1271 50569464
Neuropathy peripheral 94.15 11.37 205 34184 96552 50474183
Hepatic lesion 86.78 11.37 46 34343 3962 50566773
Contraindicated product administered 81.32 11.37 5 34384 148953 50421782
Hysteroscopy 80.50 11.37 15 34374 23 50570712
Metastases to the mediastinum 79.99 11.37 24 34365 446 50570289
Palmar-plantar erythrodysaesthesia syndrome 78.70 11.37 82 34307 20016 50550719
Osteolysis 77.92 11.37 37 34352 2520 50568215
Rheumatoid arthritis 77.36 11.37 21 34368 202529 50368206
Pseudocirrhosis 77.12 11.37 25 34364 605 50570130
Endometrial cancer 76.65 11.37 38 34351 2845 50567890
Systemic lupus erythematosus 75.93 11.37 5 34384 140617 50430118
Metastases to peritoneum 74.31 11.37 37 34352 2796 50567939
Device related thrombosis 72.99 11.37 29 34360 1278 50569457
Joint swelling 71.27 11.37 39 34350 245247 50325488
Bone pain 70.46 11.37 120 34269 47109 50523626
Death 69.87 11.37 418 33971 324961 50245774
Tonsillar disorder 68.60 11.37 26 34363 1008 50569727
Metastases to skin 67.99 11.37 28 34361 1355 50569380
Recurrent cancer 67.92 11.37 30 34359 1727 50569008
Neutropenia 66.17 11.37 236 34153 147729 50423006
Glossodynia 65.82 11.37 3 34386 115566 50455169
Endometrial atrophy 65.64 11.37 14 34375 56 50570679
Therapeutic product effect decreased 64.98 11.37 8 34381 136042 50434693
Blood uric acid decreased 63.39 11.37 22 34367 660 50570075
Nail disorder 59.93 11.37 51 34338 9657 50561078
Synovitis 59.85 11.37 7 34382 123858 50446877
Carbohydrate antigen 15-3 increased 59.35 11.37 24 34365 1108 50569627
Pleural effusion 59.07 11.37 154 34235 81300 50489435
Uterine cancer 58.66 11.37 35 34354 3785 50566950
Lymphoedema 58.53 11.37 49 34340 9073 50561662
Lymphadenopathy 57.93 11.37 91 34298 33408 50537327
Acute promyelocytic leukaemia 57.82 11.37 22 34367 862 50569873
Nasal disorder 57.18 11.37 29 34360 2279 50568456
Endocervical curettage 56.65 11.37 9 34380 0 50570735
Eosinophil percentage increased 56.10 11.37 22 34367 936 50569799
Ovarian hyperstimulation syndrome 55.83 11.37 32 34357 3212 50567523
Metastases to pelvis 55.12 11.37 17 34372 348 50570387
Ascites 53.33 11.37 91 34298 35770 50534965
Excessive eye blinking 52.86 11.37 21 34368 925 50569810
Abdominal discomfort 51.40 11.37 49 34340 231592 50339143
Breast mass 50.65 11.37 39 34350 6410 50564325
Pulmonary mass 50.59 11.37 63 34326 18642 50552093
Metastases to thorax 49.46 11.37 14 34375 210 50570525
Maternal exposure during pregnancy 48.46 11.37 24 34365 159754 50410981
Recall phenomenon 48.09 11.37 17 34372 539 50570196
Tooth extraction 46.69 11.37 43 34346 9032 50561703
Endometriosis 46.66 11.37 31 34358 4044 50566691
Breast cancer female 46.40 11.37 38 34351 6824 50563911
Wound 46.39 11.37 8 34381 105786 50464949
Completed suicide 46.14 11.37 16 34373 131873 50438862
Hepatic enzyme increased 45.81 11.37 18 34371 137362 50433373
Disease recurrence 45.53 11.37 62 34327 20019 50550716
Lymphangiosis carcinomatosa 44.88 11.37 20 34369 1176 50569559
Ovarian cancer 44.56 11.37 33 34356 5116 50565619
Left ventricular dilatation 44.44 11.37 15 34374 413 50570322
Peritoneal disorder 43.77 11.37 15 34374 433 50570302
Dural arteriovenous fistula 43.45 11.37 8 34381 11 50570724
Metastases to ovary 43.29 11.37 14 34375 336 50570399
Vitreous detachment 42.87 11.37 22 34367 1772 50568963
Metastases to chest wall 42.82 11.37 15 34374 463 50570272
Retinopathy 42.04 11.37 25 34364 2687 50568048
Hypertriglyceridaemia 40.51 11.37 32 34357 5459 50565276
Ejection fraction decreased 40.21 11.37 56 34333 18464 50552271
Haematotoxicity 39.83 11.37 37 34352 7858 50562877
Polyneuropathy 39.64 11.37 45 34344 12086 50558649
Metastatic neoplasm 39.26 11.37 27 34362 3727 50567008
Cerebral venous thrombosis 39.17 11.37 21 34368 1850 50568885
Sinusitis 39.09 11.37 35 34354 170523 50400212
Lymphadenopathy mediastinal 38.54 11.37 23 34366 2488 50568247
Onycholysis 36.78 11.37 18 34371 1310 50569425
Pneumonia 36.69 11.37 133 34256 378268 50192467
Metastases to muscle 36.44 11.37 10 34379 133 50570602
Bronchomalacia 36.34 11.37 11 34378 211 50570524
Vulvovaginal dryness 35.84 11.37 21 34368 2196 50568539
Hypersensitivity 35.64 11.37 57 34332 215104 50355631
Exposure during pregnancy 35.46 11.37 19 34370 120996 50449739
Pulmonary embolism 35.44 11.37 150 34239 101554 50469181
Swelling 35.40 11.37 51 34338 200821 50369914
BRAF gene mutation 34.97 11.37 8 34381 47 50570688
Spinal cord compression 34.89 11.37 25 34364 3684 50567051
Rash 34.81 11.37 166 34223 437305 50133430
Endometrial disorder 34.75 11.37 14 34375 640 50570095
Portal hypertension 34.54 11.37 24 34365 3368 50567367
Endometrial thickening 34.21 11.37 11 34378 259 50570476
Exposed bone in jaw 33.76 11.37 22 34367 2778 50567957
Drug hypersensitivity 33.26 11.37 76 34313 250934 50319801
Condition aggravated 33.21 11.37 98 34291 296960 50273775
Blood creatinine decreased 32.48 11.37 27 34362 4949 50565786
Hepatic cirrhosis 32.13 11.37 49 34340 17528 50553207
Bone cancer metastatic 32.04 11.37 9 34380 131 50570604
Metastases to uterus 31.89 11.37 8 34381 73 50570662
Treatment failure 31.82 11.37 28 34361 137609 50433126
Hypertransaminasaemia 30.93 11.37 23 34366 3588 50567147
Infusion related reaction 30.92 11.37 42 34347 169515 50401220
Uterine leiomyoma 30.54 11.37 32 34357 7859 50562876
Pleural disorder 30.05 11.37 12 34377 536 50570199
Hydrothorax 29.94 11.37 13 34376 718 50570017
Menopause 29.82 11.37 19 34370 2308 50568427
Malignant pleural effusion 29.80 11.37 19 34370 2311 50568424
Menopausal disorder 29.54 11.37 7 34382 49 50570686
Tumour invasion 29.53 11.37 8 34381 101 50570634
Osteosclerosis 29.51 11.37 22 34367 3445 50567290
Product use issue 29.35 11.37 35 34354 149440 50421295
Cervical polyp 28.74 11.37 9 34380 194 50570541
Adenocarcinoma 28.71 11.37 19 34370 2462 50568273
Invasive ductal breast carcinoma 28.43 11.37 27 34362 5894 50564841
Nasopharyngitis 28.41 11.37 55 34334 192872 50377863
Acquired gene mutation 28.34 11.37 13 34376 818 50569917
Adnexa uteri mass 27.98 11.37 11 34378 471 50570264
Radiation skin injury 27.87 11.37 13 34376 850 50569885
Radiation necrosis 27.82 11.37 10 34379 333 50570402
Left ventricular dysfunction 27.79 11.37 35 34354 10471 50560264
Uterine dilation and curettage 27.74 11.37 13 34376 859 50569876
Cardiac cirrhosis 27.61 11.37 8 34381 131 50570604
Neoplasm recurrence 27.07 11.37 18 34371 2351 50568384
Osteitis condensans 26.88 11.37 6 34383 31 50570704
Pericarditis 26.74 11.37 10 34379 78679 50492056
Injection site pain 26.38 11.37 22 34367 111002 50459733
Oestradiol abnormal 26.26 11.37 6 34383 35 50570700
Mucosal inflammation 26.17 11.37 73 34316 40069 50530666
RET gene mutation 25.99 11.37 5 34384 10 50570725
Jaw operation 25.97 11.37 12 34377 768 50569967
Gastrointestinal toxicity 25.71 11.37 23 34366 4654 50566081
Breast cancer stage IV 25.43 11.37 11 34378 602 50570133
Porphyria non-acute 25.38 11.37 9 34380 288 50570447
Tympanic membrane disorder 25.27 11.37 8 34381 179 50570556
Radiation pneumonitis 25.22 11.37 14 34375 1321 50569414
Drug abuse 25.21 11.37 5 34384 59841 50510894
Metastases to stomach 25.02 11.37 8 34381 185 50570550
Bone sequestrum 24.81 11.37 14 34375 1364 50569371
Malignant neoplasm of pleura 24.73 11.37 6 34383 47 50570688
Mucosal toxicity 24.67 11.37 9 34380 313 50570422
Pain in jaw 24.18 11.37 69 34320 38359 50532376
Gingival bleeding 24.15 11.37 34 34355 11319 50559416
Arthropathy 24.14 11.37 44 34345 157862 50412873
Tumour marker decreased 23.61 11.37 6 34383 58 50570677
Actinomycosis 23.49 11.37 12 34377 957 50569778
Pain 23.15 11.37 267 34122 578636 49992099
Deprescribing error 23.06 11.37 5 34384 22 50570713
Jaw disorder 22.71 11.37 22 34367 4921 50565814
Vaginal haemorrhage 22.69 11.37 51 34338 24500 50546235
Leiomyoma 22.60 11.37 9 34380 399 50570336
Pathological fracture 22.60 11.37 27 34362 7655 50563080
Central nervous system lesion 22.58 11.37 30 34359 9459 50561276
Maculopathy 22.56 11.37 15 34374 1959 50568776
Sequestrectomy 22.42 11.37 11 34378 805 50569930
Dental operation 22.13 11.37 12 34377 1081 50569654
Metastases to breast 22.02 11.37 8 34381 275 50570460
Hysterectomy 22.02 11.37 27 34362 7863 50562872
Metastases to bone marrow 21.99 11.37 8 34381 276 50570459
Skin hypopigmentation 21.92 11.37 10 34379 621 50570114
Eastern Cooperative Oncology Group performance status worsened 21.82 11.37 10 34379 628 50570107
Hepatic steatosis 21.81 11.37 50 34339 24334 50546401
Fibrous histiocytoma 21.57 11.37 9 34380 450 50570285
Malignant neoplasm of choroid 21.52 11.37 4 34385 6 50570729
Toothache 21.42 11.37 40 34349 16854 50553881
HER2 positive breast cancer 21.28 11.37 8 34381 303 50570432
Invasive lobular breast carcinoma 21.28 11.37 10 34379 665 50570070
Abdominal lymphadenopathy 21.20 11.37 10 34379 671 50570064
Atrophic vulvovaginitis 20.38 11.37 13 34376 1583 50569152
Jaundice 20.20 11.37 51 34338 26378 50544357
Osteomyelitis 20.17 11.37 46 34343 22307 50548428
Infection 20.07 11.37 56 34333 172898 50397837
Injection site extravasation 19.86 11.37 25 34364 7476 50563259
Discomfort 19.59 11.37 27 34362 108353 50462382
Neoplasm 19.38 11.37 22 34367 5906 50564829
Meningeal disorder 19.26 11.37 7 34382 241 50570494
Therapy partial responder 19.11 11.37 23 34366 6568 50564167
Polypectomy 19.00 11.37 9 34380 609 50570126
Congestive cardiomyopathy 18.93 11.37 21 34368 5497 50565238
Amenorrhoea 18.93 11.37 26 34363 8458 50562277
Uterine polypectomy 18.88 11.37 3 34386 0 50570735
Pulmonary radiation injury 18.88 11.37 3 34386 0 50570735
Weight increased 18.84 11.37 72 34317 201819 50368916
Ovarian cyst 18.83 11.37 34 34355 13962 50556773
Carcinoembryonic antigen increased 18.80 11.37 12 34377 1462 50569273
Portal vein thrombosis 18.75 11.37 14 34375 2198 50568537
Oestrogen receptor assay positive 18.54 11.37 8 34381 435 50570300
Neutrophilia 18.51 11.37 17 34372 3558 50567177
Adenomyosis 18.19 11.37 8 34381 456 50570279
Product dose omission issue 18.18 11.37 64 34325 183774 50386961
Myelodysplastic syndrome 18.16 11.37 35 34354 15097 50555638
Gastrointestinal haemorrhage 18.07 11.37 14 34375 73307 50497428
Breath odour 18.04 11.37 11 34378 1237 50569498
Activated PI3 kinase delta syndrome 18.03 11.37 4 34385 20 50570715
Oophorectomy 17.97 11.37 8 34381 469 50570266
Lymphangioleiomyomatosis 17.96 11.37 6 34383 160 50570575
Cardiotoxicity 17.94 11.37 23 34366 7004 50563731
Toxicity to various agents 17.82 11.37 79 34310 212420 50358315
Disturbance in attention 17.72 11.37 54 34335 31132 50539603
Peripheral swelling 17.61 11.37 76 34313 205860 50364875
Breast disorder 17.59 11.37 13 34376 2009 50568726
Aeromonas infection 17.54 11.37 5 34384 77 50570658
Breast neoplasm 17.53 11.37 11 34378 1302 50569433
Corneal degeneration 17.48 11.37 5 34384 78 50570657
Menopausal symptoms 17.47 11.37 13 34376 2030 50568705
Macular hole 17.43 11.37 9 34380 734 50570001
Somnolence 17.38 11.37 51 34338 154934 50415801
Therapeutic product effect incomplete 17.35 11.37 22 34367 91493 50479242
Corneal graft rejection 17.14 11.37 4 34385 26 50570709
Paraneoplastic syndrome 17.12 11.37 8 34381 525 50570210
Headache 17.11 11.37 242 34147 506293 50064442
Respiratory tract inflammation 17.02 11.37 8 34381 532 50570203
Ventricular hypokinesia 16.96 11.37 17 34372 3963 50566772
Pruritus 16.91 11.37 118 34271 283450 50287285
Oxygen saturation decreased 16.80 11.37 15 34374 73233 50497502
Cortisol increased 16.72 11.37 7 34382 353 50570382
Intentional overdose 16.63 11.37 11 34378 62493 50508242
Diabetic hyperosmolar coma 16.56 11.37 7 34382 362 50570373
Loss of personal independence in daily activities 16.49 11.37 14 34375 70036 50500699
Contusion 16.49 11.37 32 34357 112151 50458584
Invasive breast carcinoma 16.41 11.37 8 34381 577 50570158
Acute lymphocytic leukaemia 16.40 11.37 13 34376 2228 50568507
Atrial thrombosis 16.34 11.37 11 34378 1466 50569269
Sensory loss 16.20 11.37 23 34366 7715 50563020
Performance status decreased 16.17 11.37 15 34374 3180 50567555
Debridement 16.05 11.37 10 34379 1169 50569566
Gingivitis 15.77 11.37 22 34367 7262 50563473
Myalgia 15.75 11.37 141 34248 124178 50446557
Libido decreased 15.73 11.37 13 34376 2363 50568372
Acarodermatitis 15.56 11.37 9 34380 919 50569816
Hypotension 15.54 11.37 95 34294 235374 50335361
Arteriovenous malformation 15.45 11.37 10 34379 1248 50569487
Oral pustule 15.44 11.37 4 34385 42 50570693
Liver scan abnormal 15.44 11.37 4 34385 42 50570693
Salpingitis 15.42 11.37 6 34383 250 50570485
Intermenstrual bleeding 15.38 11.37 21 34368 6793 50563942
Uterine haemorrhage 15.32 11.37 15 34374 3400 50567335
Septic shock 15.29 11.37 10 34379 57165 50513570
Rapidly progressive osteoarthritis 15.28 11.37 3 34386 7 50570728
Respiratory tract oedema 15.25 11.37 7 34382 441 50570294
Metastases to eye 15.19 11.37 5 34384 127 50570608
Blood alkaline phosphatase increased 15.18 11.37 58 34331 37468 50533267
Central nervous system infection 15.13 11.37 8 34381 685 50570050
Acute kidney injury 15.06 11.37 92 34297 227966 50342769
Blood bilirubin increased 15.06 11.37 52 34337 31986 50538749
Paraesthesia 15.04 11.37 136 34253 120107 50450628
Urticaria 14.99 11.37 42 34347 129519 50441216
Rhabdomyolysis 14.96 11.37 4 34385 39023 50531712
Deafness 14.95 11.37 33 34356 15658 50555077
Vertebral lesion 14.92 11.37 7 34382 464 50570271
Haemangioma of liver 14.87 11.37 9 34380 999 50569736
Chronic hepatic failure 14.78 11.37 7 34382 474 50570261
Periodontitis 14.74 11.37 14 34375 3055 50567680
Blood follicle stimulating hormone decreased 14.73 11.37 3 34386 9 50570726
Oesophageal varices haemorrhage 14.69 11.37 9 34380 1021 50569714
Alopecia 14.59 11.37 102 34287 244945 50325790
Cerebral haemorrhage 14.59 11.37 46 34343 27006 50543729
Salpingo-oophorectomy bilateral 14.57 11.37 5 34384 145 50570590
Coagulation factor V level decreased 14.50 11.37 6 34383 294 50570441
Blood copper increased 14.49 11.37 3 34386 10 50570725
Musculoskeletal chest pain 14.47 11.37 36 34353 18450 50552285
Skin exfoliation 14.47 11.37 53 34336 33559 50537176
Blood follicle stimulating hormone increased 14.38 11.37 5 34384 151 50570584
Primary adrenal insufficiency 14.32 11.37 4 34385 57 50570678
Breast cancer in situ 14.28 11.37 10 34379 1421 50569314
Adenoid cystic carcinoma 14.27 11.37 3 34386 11 50570724
Non-alcoholic steatohepatitis 14.25 11.37 10 34379 1425 50569310
Injection site erythema 14.22 11.37 18 34371 74918 50495817
Blood lactate dehydrogenase increased 14.18 11.37 37 34352 19525 50551210
Trigger finger 14.01 11.37 15 34374 3773 50566962
Atypical femur fracture 14.00 11.37 17 34372 4899 50565836
Cardiomyopathy 13.98 11.37 32 34357 15554 50555181
Ocular toxicity 13.95 11.37 7 34382 538 50570197
Retinal artery occlusion 13.93 11.37 10 34379 1477 50569258
Varices oesophageal 13.93 11.37 13 34376 2776 50567959
Pelvic mass 13.86 11.37 9 34380 1130 50569605
Encephalopathy 13.82 11.37 3 34386 33708 50537027
Blister 13.77 11.37 23 34366 85395 50485340
Multiple sclerosis relapse 13.71 11.37 6 34383 42958 50527777
Hepatic cancer metastatic 13.66 11.37 6 34383 341 50570394
Nasal congestion 13.59 11.37 9 34380 51111 50519624
Oral mucosal hypertrophy 13.52 11.37 3 34386 15 50570720
Diverticulitis 13.50 11.37 3 34386 33179 50537556
Visual acuity reduced 13.49 11.37 37 34352 20102 50550633
Postmenopausal haemorrhage 13.46 11.37 11 34378 1969 50568766
Metastases to neck 13.45 11.37 4 34385 72 50570663
Sepsis 13.32 11.37 46 34343 132879 50437856
Papillary thyroid cancer 13.29 11.37 11 34378 2004 50568731
Knee arthroplasty 13.14 11.37 4 34385 35842 50534893
Corneal disorder 13.13 11.37 10 34379 1616 50569119
Nasal dryness 12.94 11.37 14 34375 3565 50567170
Madarosis 12.92 11.37 12 34377 2548 50568187
Drug resistance 12.83 11.37 35 34354 18954 50551781
Reversible cerebral vasoconstriction syndrome 12.81 11.37 11 34378 2108 50568627
Oestradiol increased 12.78 11.37 4 34385 86 50570649
Internal fixation of fracture 12.66 11.37 7 34382 655 50570080
Hepatotoxicity 12.63 11.37 44 34345 27182 50543553
Eosinophil count increased 12.59 11.37 22 34367 8808 50561927
Myocardial infarction 12.56 11.37 26 34363 89001 50481734
Lower limb fracture 12.50 11.37 29 34360 14217 50556518
Neoplasm malignant 12.49 11.37 40 34349 23675 50547060
Breast reconstruction 12.48 11.37 5 34384 225 50570510
Desmoid tumour 12.41 11.37 4 34385 95 50570640
Vein disorder 12.41 11.37 15 34374 4304 50566431
Purulent discharge 12.37 11.37 15 34374 4317 50566418
Alopecia areata 12.36 11.37 9 34380 1359 50569376
Breast pain 12.36 11.37 20 34369 7524 50563211
Metastases to adrenals 12.36 11.37 7 34382 687 50570048
Retroperitoneal neoplasm metastatic 12.31 11.37 3 34386 24 50570711
Abdominal pain upper 12.30 11.37 61 34328 159248 50411487
Incorrect dose administered 12.24 11.37 9 34380 48405 50522330
Superior sagittal sinus thrombosis 12.23 11.37 7 34382 700 50570035
Pneumonia aspiration 12.23 11.37 3 34386 31001 50539734
Dental caries 12.06 11.37 23 34366 9844 50560891
Tooth disorder 11.98 11.37 40 34349 24188 50546547
Influenza 11.93 11.37 27 34362 89511 50481224
Endometrial adenocarcinoma 11.88 11.37 8 34381 1067 50569668
Bile duct stenosis 11.87 11.37 8 34381 1068 50569667
Hydronephrosis 11.81 11.37 21 34368 8520 50562215
Injection site reaction 11.77 11.37 10 34379 50022 50520713
Folliculitis 11.71 11.37 6 34383 39219 50531516
Intestinal metastasis 11.69 11.37 4 34385 115 50570620
Fungal disease carrier 11.62 11.37 3 34386 31 50570704
Ovarian granulosa-theca cell tumour 11.62 11.37 3 34386 31 50570704
HER2 gene amplification 11.62 11.37 3 34386 31 50570704
Psoriatic arthropathy 11.56 11.37 9 34380 47023 50523712
Glutamate dehydrogenase increased 11.45 11.37 3 34386 33 50570702
Heart rate irregular 11.44 11.37 34 34355 19326 50551409

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metastases to bone 81.86 28.34 25 1042 9873 29563587
Carbohydrate antigen 15-3 increased 63.67 28.34 9 1058 69 29573391
Metastases to lung 44.92 28.34 15 1052 7840 29565620
Metastases to central nervous system 34.43 28.34 12 1055 7119 29566341
Malignant neoplasm progression 33.87 28.34 25 1042 73834 29499626
Metastases to the mediastinum 33.55 28.34 6 1061 223 29573237
PIK3CA-activated mutation 31.19 28.34 5 1062 95 29573365
Hepatic lesion 30.50 28.34 9 1058 3141 29570319

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metastases to bone 1150.36 12.26 401 26799 20034 64451498
Malignant neoplasm progression 751.07 12.26 510 26690 112361 64359171
Metastases to liver 496.82 12.26 229 26971 23712 64447820
Metastases to lung 429.89 12.26 181 27019 15083 64456449
Metastases to lymph nodes 348.26 12.26 133 27067 8584 64462948
Breast cancer metastatic 310.34 12.26 116 27084 7053 64464479
Breast cancer recurrent 308.52 12.26 90 27110 2493 64469039
Breast cancer 220.51 12.26 143 27057 29005 64442527
Neoplasm progression 211.57 12.26 159 27041 40805 64430727
Osteonecrosis of jaw 189.00 12.26 147 27053 39678 64431854
Disease progression 184.31 12.26 261 26939 141419 64330113
Metastases to central nervous system 140.24 12.26 82 27118 13830 64457702
Metastases to spine 136.25 12.26 53 27147 3590 64467942
Hot flush 121.40 12.26 122 27078 46113 64425419
Bone lesion 118.67 12.26 53 27147 5084 64466448
Sarcoma uterus 116.72 12.26 18 27182 6 64471526
Tumour marker increased 107.50 12.26 44 27156 3406 64468126
Osteonecrosis 102.06 12.26 89 27111 28140 64443392
Second primary malignancy 96.90 12.26 62 27138 12275 64459257
Acute myeloid leukaemia 94.12 12.26 84 27116 27379 64444153
Metastases to skin 91.29 12.26 31 27169 1421 64470111
Metastasis 89.31 12.26 45 27155 5650 64465882
PIK3CA-activated mutation 88.69 12.26 24 27176 501 64471031
Hepatic lesion 88.35 12.26 45 27155 5779 64465753
Metastases to the mediastinum 88.29 12.26 24 27176 510 64471022
Pseudocirrhosis 83.80 12.26 24 27176 621 64470911
Endometrial cancer 82.98 12.26 31 27169 1879 64469653
Endometrial hyperplasia 80.29 12.26 22 27178 482 64471050
Neuropathy peripheral 79.66 12.26 162 27038 117363 64354169
Uterine polyp 78.33 12.26 27 27173 1295 64470237
Carbohydrate antigen 15-3 increased 77.81 12.26 25 27175 962 64470570
Bone disorder 77.60 12.26 61 27139 16698 64454834
Breast mass 77.57 12.26 40 27160 5270 64466262
Tonsillar disorder 77.47 12.26 25 27175 976 64470556
Metastases to pleura 71.75 12.26 25 27175 1239 64470293
Endometrial atrophy 71.34 12.26 13 27187 34 64471498
Lymphadenopathy 66.56 12.26 90 27110 46596 64424936
Device related thrombosis 66.35 12.26 27 27173 2058 64469474
Nasal disorder 64.21 12.26 29 27171 2855 64468677
Osteolysis 61.81 12.26 28 27172 2775 64468757
Hormone receptor positive breast cancer 60.65 12.26 16 27184 302 64471230
Blood uric acid decreased 59.43 12.26 21 27179 1085 64470447
Acute promyelocytic leukaemia 58.38 12.26 22 27178 1366 64470166
Nail disorder 57.19 12.26 39 27161 8585 64462947
Bone pain 56.43 12.26 84 27116 47488 64424044
Eosinophil percentage increased 54.25 12.26 21 27179 1403 64470129
Completed suicide 54.00 12.26 14 27186 224400 64247132
Lymphoedema 52.32 12.26 39 27161 9866 64461666
Recurrent cancer 50.11 12.26 23 27177 2350 64469182
Metastases to chest wall 48.35 12.26 14 27186 377 64471155
Metastases to pelvis 48.10 12.26 15 27185 523 64471009
Disease recurrence 46.83 12.26 62 27138 31448 64440084
Pulmonary mass 46.54 12.26 54 27146 23962 64447570
Recall phenomenon 46.17 12.26 17 27183 989 64470543
Lymphangiosis carcinomatosa 45.97 12.26 20 27180 1801 64469731
Excessive eye blinking 45.95 12.26 18 27182 1242 64470290
Vitreous detachment 44.72 12.26 20 27180 1924 64469608
Endometrial hypertrophy 44.50 12.26 11 27189 158 64471374
Metastases to peritoneum 44.11 12.26 24 27176 3523 64468009
Breast cancer female 43.46 12.26 27 27173 5076 64466456
Cerebral venous thrombosis 43.36 12.26 21 27179 2420 64469112
Lymphadenopathy mediastinal 42.12 12.26 24 27176 3852 64467680
Bronchomalacia 41.53 12.26 11 27189 211 64471321
Peritoneal disorder 41.36 12.26 14 27186 635 64470897
Left ventricular dilatation 40.03 12.26 15 27185 917 64470615
Uterine cancer 39.95 12.26 21 27179 2877 64468655
Retinopathy 39.73 12.26 22 27178 3343 64468189
Metastases to ovary 39.72 12.26 11 27189 251 64471281
Invasive ductal breast carcinoma 38.75 12.26 25 27175 5017 64466515
Adnexa uteri mass 38.39 12.26 11 27189 285 64471247
Pulmonary embolism 38.16 12.26 142 27058 146214 64325318
Pneumonia 37.87 12.26 116 27084 559460 63912072
Endometrial thickening 37.84 12.26 10 27190 190 64471342
Endometriosis 37.83 12.26 20 27180 2772 64468760
Joint swelling 37.72 12.26 22 27178 215360 64256172
Ovarian cancer 37.28 12.26 21 27179 3298 64468234
Drug ineffective 35.93 12.26 208 26992 840039 63631493
Haematotoxicity 35.62 12.26 35 27165 12861 64458671
Vulvovaginal dryness 35.26 12.26 16 27184 1592 64469940
Maculopathy 34.16 12.26 18 27182 2478 64469054
Menopausal disorder 34.09 12.26 7 27193 40 64471492
Acute kidney injury 33.40 12.26 89 27111 449151 64022381
Palmar-plantar erythrodysaesthesia syndrome 32.90 12.26 50 27150 28769 64442763
Uterine leiomyoma 32.59 12.26 23 27177 5346 64466186
Pleural disorder 32.24 12.26 12 27188 720 64470812
Tooth extraction 32.16 12.26 29 27171 9572 64461960
Hypertriglyceridaemia 32.05 12.26 31 27169 11174 64460358
Metastases to eye 32.03 12.26 9 27191 217 64471315
Pathological fracture 31.75 12.26 28 27172 8977 64462555
Pleural effusion 31.50 12.26 121 27079 126438 64345094
Menopause 31.27 12.26 15 27185 1693 64469839
Blood creatinine decreased 31.21 12.26 25 27175 7025 64464507
Neutropenia 31.16 12.26 190 27010 239434 64232098
Ejection fraction decreased 30.25 12.26 48 27152 28659 64442873
Rheumatoid arthritis 29.89 12.26 16 27184 164278 64307254
Osteitis condensans 29.73 12.26 6 27194 31 64471501
Contraindicated product administered 29.47 12.26 5 27195 107824 64363708
Radiation pneumonitis 29.33 12.26 18 27182 3310 64468222
Metastases to thorax 29.30 12.26 8 27192 173 64471359
Tympanic membrane disorder 29.21 12.26 8 27192 175 64471357
Ascites 29.17 12.26 74 27126 61927 64409605
Radiation necrosis 28.61 12.26 9 27191 323 64471209
Therapeutic product effect decreased 28.11 12.26 7 27193 115344 64356188
Toxicity to various agents 27.77 12.26 71 27129 363442 64108090
Cardiac cirrhosis 27.75 12.26 8 27192 212 64471320
Tumour marker decreased 27.69 12.26 6 27194 46 64471486
Portal hypertension 27.42 12.26 22 27178 6197 64465335
Metastases to uterus 26.64 12.26 6 27194 56 64471476
Hypertransaminasaemia 26.64 12.26 23 27177 7168 64464364
Atrophic vulvovaginitis 26.49 12.26 12 27188 1189 64470343
Menopausal symptoms 26.21 12.26 13 27187 1577 64469955
Synovitis 26.20 12.26 5 27195 99085 64372447
Exposed bone in jaw 26.08 12.26 17 27183 3470 64468062
Malignant pleural effusion 26.03 12.26 16 27184 2951 64468581
Deprescribing error 25.25 12.26 5 27195 23 64471509
Mucosal toxicity 25.14 12.26 9 27191 483 64471049
Hepatic cirrhosis 25.04 12.26 42 27158 26256 64445276
Hepatic steatosis 24.96 12.26 46 27154 30961 64440571
Left ventricular dysfunction 24.63 12.26 33 27167 16921 64454611
Metastatic neoplasm 24.61 12.26 18 27182 4424 64467108
Sepsis 24.49 12.26 37 27163 230304 64241228
Fibrous histiocytoma 24.34 12.26 9 27191 530 64471002
Vaginal haemorrhage 24.15 12.26 35 27165 19309 64452223
Gastrointestinal haemorrhage 23.89 12.26 13 27187 132299 64339233
Lower limb fracture 23.84 12.26 29 27171 13516 64458016
Gastrointestinal toxicity 23.83 12.26 19 27181 5303 64466229
Sequestrectomy 23.66 12.26 10 27190 839 64470693
Disturbance in attention 23.62 12.26 53 27147 41021 64430511
Breast cancer in situ 23.40 12.26 10 27190 862 64470670
Paraesthesia 23.06 12.26 115 27085 134407 64337125
Septic shock 22.77 12.26 8 27192 105429 64366103
RET gene mutation 22.70 12.26 4 27196 8 64471524
Systemic lupus erythematosus 22.58 12.26 3 27197 77609 64393923
Myocardial infarction 22.53 12.26 22 27178 165799 64305733
Injection site extravasation 22.43 12.26 22 27178 8064 64463468
Radiation skin injury 22.30 12.26 11 27189 1319 64470213
Hypotension 22.30 12.26 84 27116 380890 64090642
Cervical polyp 22.14 12.26 6 27194 126 64471406
Adenomyosis 21.92 12.26 7 27193 264 64471268
Porphyria non-acute 21.80 12.26 9 27191 712 64470820
Invasive breast carcinoma 21.72 12.26 8 27192 466 64471066
Gingival bleeding 21.72 12.26 29 27171 14825 64456707
Therapy partial responder 21.47 12.26 24 27176 10224 64461308
Cardiotoxicity 21.43 12.26 24 27176 10250 64461282
Lymphangioleiomyomatosis 21.42 12.26 6 27194 143 64471389
Osteosclerosis 21.31 12.26 15 27185 3471 64468061
Abdominal lymphadenopathy 20.95 12.26 10 27190 1116 64470416
Toothache 20.94 12.26 31 27169 17428 64454104
Invasive lobular breast carcinoma 20.63 12.26 8 27192 537 64470995
Leiomyoma 20.57 12.26 7 27193 323 64471209
Arteriovenous malformation 20.54 12.26 11 27189 1565 64469967
Amenorrhoea 20.43 12.26 19 27181 6520 64465012
Hepatic enzyme increased 20.39 12.26 15 27185 129928 64341604
Onycholysis 20.22 12.26 11 27189 1615 64469917
Oestradiol abnormal 20.10 12.26 4 27196 19 64471513
Tumour invasion 20.07 12.26 7 27193 348 64471184
Sensory loss 19.93 12.26 23 27177 10146 64461386
Breast disorder 19.85 12.26 11 27189 1673 64469859
Atypical femur fracture 19.41 12.26 16 27184 4682 64466850
Metastases to meninges 19.30 12.26 13 27187 2802 64468730
Ovarian hyperstimulation syndrome 19.18 12.26 13 27187 2832 64468700
Superior sagittal sinus thrombosis 19.18 12.26 9 27191 967 64470565
Meningeal disorder 19.03 12.26 7 27193 406 64471126
Madarosis 19.01 12.26 12 27188 2318 64469214
Postmenopausal haemorrhage 18.66 12.26 10 27190 1425 64470107
Drug abuse 18.64 12.26 17 27183 132357 64339175
Cortisol increased 18.58 12.26 7 27193 434 64471098
Vertebral lesion 18.54 12.26 7 27193 437 64471095
Ovarian cyst 18.44 12.26 23 27177 10995 64460537
Deafness 18.39 12.26 30 27170 18329 64453203
Multiple organ dysfunction syndrome 18.26 12.26 10 27190 101403 64370129
Metastases to stomach 18.17 12.26 6 27194 252 64471280
Polyneuropathy 17.92 12.26 31 27169 19863 64451669
Respiratory tract inflammation 17.76 12.26 8 27192 782 64470750
Glossodynia 17.67 12.26 3 27197 64693 64406839
Corneal degeneration 17.66 12.26 5 27195 124 64471408
Bone sequestrum 17.61 12.26 9 27191 1163 64470369
Pain in jaw 17.49 12.26 47 27153 40708 64430824
Oxygen saturation decreased 17.30 12.26 12 27188 107164 64364368
Acarodermatitis 17.19 12.26 9 27191 1223 64470309
Breast neoplasm 17.15 12.26 8 27192 848 64470684
Central nervous system lesion 17.12 12.26 23 27177 11826 64459706
Eastern Cooperative Oncology Group performance status worsened 17.08 12.26 9 27191 1239 64470293
Hydrothorax 17.02 12.26 9 27191 1248 64470284
Liver scan abnormal 16.77 12.26 4 27196 49 64471483
Nasal dryness 16.68 12.26 13 27187 3513 64468019
Paraneoplastic syndrome 16.66 12.26 8 27192 905 64470627
Trigger finger 16.61 12.26 13 27187 3532 64468000
Reversible cerebral vasoconstriction syndrome 16.50 12.26 11 27189 2331 64469201
Corneal graft rejection 16.48 12.26 4 27196 53 64471479
Treatment failure 16.45 12.26 15 27185 116801 64354731
Actinomycosis 16.42 12.26 8 27192 934 64470598
Neutrophilia 16.35 12.26 17 27183 6677 64464855
Hair texture abnormal 16.25 12.26 12 27188 2992 64468540
Intermenstrual bleeding 16.23 12.26 15 27185 5110 64466422
Wound 16.17 12.26 6 27194 76471 64395061
Metabolic acidosis 15.99 12.26 5 27195 70953 64400579
Cardio-respiratory arrest 15.91 12.26 11 27189 98382 64373150
Non-alcoholic steatohepatitis 15.80 12.26 10 27190 1942 64469590
Rapidly progressive osteoarthritis 15.70 12.26 3 27197 11 64471521
Haemangioma of liver 15.53 12.26 8 27192 1052 64470480
Corneal disorder 15.45 12.26 10 27190 2017 64469515
Breath odour 15.40 12.26 9 27191 1515 64470017
Alopecia areata 15.38 12.26 9 27191 1519 64470013
Diabetic hyperosmolar coma 15.31 12.26 7 27193 709 64470823
BRCA2 gene mutation 15.29 12.26 4 27196 73 64471459
Hypersensitivity 15.27 12.26 38 27162 196414 64275118
Respiratory tract oedema 15.18 12.26 7 27193 723 64470809
Adenocarcinoma 15.08 12.26 12 27188 3339 64468193
Jaw operation 14.92 12.26 7 27193 752 64470780
Spinal cord compression 14.87 12.26 15 27185 5688 64465844
Debridement 14.86 12.26 9 27191 1617 64469915
Hysteroscopy 14.78 12.26 3 27197 16 64471516
Oral mucosal hypertrophy 14.78 12.26 3 27197 16 64471516
Breast reconstruction 14.67 12.26 4 27196 86 64471446
Portal vein thrombosis 14.64 12.26 14 27186 4977 64466555
Adenoid cystic carcinoma 14.63 12.26 3 27197 17 64471515
Central nervous system infection 14.63 12.26 8 27192 1186 64470346
Metastases to breast 14.50 12.26 5 27195 240 64471292
Retinal artery occlusion 14.38 12.26 11 27189 2892 64468640
Encapsulating peritoneal sclerosis 14.36 12.26 7 27193 818 64470714
Oestradiol increased 14.33 12.26 4 27196 94 64471438
Respiratory failure 14.30 12.26 29 27171 161154 64310378
Cystoid macular oedema 14.14 12.26 9 27191 1765 64469767
Dyspareunia 14.12 12.26 9 27191 1768 64469764
Chronic hepatic failure 14.09 12.26 7 27193 852 64470680
Sinusitis 14.04 12.26 25 27175 145903 64325629
Hair colour changes 13.97 12.26 12 27188 3715 64467817
Neoplasm recurrence 13.93 12.26 12 27188 3727 64467805
Atrial thrombosis 13.92 12.26 11 27189 3031 64468501
Back pain 13.91 12.26 164 27036 250007 64221525
Coma 13.89 12.26 10 27190 87605 64383927
Breast pain 13.88 12.26 16 27184 7045 64464487
Performance status decreased 13.78 12.26 14 27186 5350 64466182
Carcinoembryonic antigen increased 13.69 12.26 9 27191 1864 64469668
Pneumonia aspiration 13.67 12.26 4 27196 59267 64412265
Endometrial adenocarcinoma 13.55 12.26 7 27193 925 64470607
Encephalopathy 13.51 12.26 4 27196 58815 64412717
Dental operation 13.41 12.26 7 27193 945 64470587
Intentional overdose 13.33 12.26 11 27189 89933 64381599
Ovarian granulosa-theca cell tumour 13.32 12.26 3 27197 28 64471504
Mucosal inflammation 13.30 12.26 57 27143 62527 64409005
Femur fracture 13.29 12.26 38 27162 34097 64437435
Coagulation factor V level decreased 13.26 12.26 6 27194 593 64470939
Metastases to muscle 13.11 12.26 5 27195 321 64471211
Skin exfoliation 12.91 12.26 45 27155 44840 64426692
Aeromonas infection 12.89 12.26 5 27195 336 64471196
Product use issue 12.87 12.26 28 27172 151687 64319845
Abdominal discomfort 12.85 12.26 37 27163 182285 64289247
Gingivitis 12.84 12.26 16 27184 7643 64463889
Ocular toxicity 12.83 12.26 6 27194 640 64470892
Atypical fracture 12.74 12.26 6 27194 650 64470882
Cardiomyopathy 12.70 12.26 31 27169 25325 64446207
Ventricular hypokinesia 12.65 12.26 16 27184 7753 64463779
Rhabdomyolysis 12.65 12.26 12 27188 91714 64379818
Rhabdomyosarcoma 12.63 12.26 4 27196 147 64471385
Unresponsive to stimuli 12.38 12.26 3 27197 50390 64421142
Neoplasm 12.29 12.26 15 27185 7016 64464516

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L02BA01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONE ANTAGONISTS AND RELATED AGENTS
Anti-estrogens
FDA MoA N0000000168 Selective Estrogen Receptor Modulators
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018931 Antineoplastic Agents, Hormonal
MeSH PA D050071 Bone Density Conservation Agents
MeSH PA D004965 Estrogen Antagonists
MeSH PA D020847 Estrogen Receptor Modulators
MeSH PA D006727 Hormone Antagonists
MeSH PA D020845 Selective Estrogen Receptor Modulators
FDA EPC N0000175826 Estrogen Agonist/Antagonist
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:37700 protein kinase C inhibitors
CHEBI has role CHEBI:48422 angiogenesis antagonist
CHEBI has role CHEBI:50646 antiosteoporotic
CHEBI has role CHEBI:50792 estrogen receptor antagonists
CHEBI has role CHEBI:50837 oestrogen antagonist
CHEBI has role CHEBI:62872 quinoline oxidase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Infiltrating duct carcinoma of breast indication 408643008 DOID:3008
Carcinoma of female breast indication 447782002
Prevention of Breast Carcinoma indication
Pain of breast off-label use 53430007
Endometrial carcinoma off-label use 254878006 DOID:2871
Malignant tumor of ovary off-label use 363443007 DOID:2394
Hypercalcemia contraindication 66931009 DOID:12678
Leukopenia contraindication 84828003 DOID:615
Bilateral cataracts contraindication 95722004
Deep venous thrombosis contraindication 128053003
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Thromboembolic disorder contraindication 371039008
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.61 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Estrogen receptor Nuclear hormone receptor MODULATOR Ki 7.51 CHEMBL CHEMBL
Beta-1 adrenergic receptor GPCR Ki 5.00 DRUG MATRIX
Prostaglandin G/H synthase 2 Enzyme IC50 4.46 WOMBAT-PK
Prostaglandin G/H synthase 1 Enzyme IC50 5.36 DRUG MATRIX
Mu-type opioid receptor GPCR Ki 5.15 DRUG MATRIX
D(1A) dopamine receptor GPCR Ki 5.37 DRUG MATRIX
D(2) dopamine receptor GPCR Ki 5.34 DRUG MATRIX
Estrogen-related receptor gamma Nuclear hormone receptor Ki 7.10 WOMBAT-PK
Adenosine receptor A2a GPCR Ki 5.40 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 6.14 DRUG MATRIX
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.50 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 5.80 CHEMBL
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Enzyme Ki 8.30 WOMBAT-PK
Multidrug resistance protein 1 Transporter Ki 7 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter Ki 5.91 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.84 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 5.16 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 5.86 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 5.88 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.62 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.98 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 5.79 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.44 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.03 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 6.17 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 5.56 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 6.20 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 6.17 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 5.73 DRUG MATRIX
Aldehyde oxidase Enzyme IC50 5.66 WOMBAT-PK
Beta-3 adrenergic receptor GPCR Ki 5.24 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.84 DRUG MATRIX
Adenosine receptor A1 GPCR Ki 4.86 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 5.68 DRUG MATRIX
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor Ki 7.46 WOMBAT-PK
D(4) dopamine receptor GPCR Ki 5.41 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 5.61 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 5.20 DRUG MATRIX
Progesterone receptor Nuclear hormone receptor IC50 6.89 CHEMBL
Delta-type opioid receptor GPCR Ki 5.33 DRUG MATRIX
Estrogen receptor beta Nuclear hormone receptor IC50 5.91 WOMBAT-PK
G-protein coupled estrogen receptor 1 GPCR IC50 7.50 WOMBAT-PK
Epidermal growth factor receptor Kinase IC50 5.45 DRUG MATRIX
Substance-P receptor GPCR Ki 5.07 DRUG MATRIX
Tyrosine-protein kinase Lck Kinase IC50 5.10 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.92 DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 5.53 DRUG MATRIX
Glucosylceramidase Enzyme EC50 5.60 CHEMBL
Thromboxane-A synthase Enzyme IC50 6.04 DRUG MATRIX
Steroid hormone receptor ERR1 Nuclear hormone receptor IC50 6.70 CHEMBL
Substance-K receptor GPCR Ki 5.91 DRUG MATRIX
B2 bradykinin receptor GPCR Ki 4.92 DRUG MATRIX
Melanocortin receptor 4 GPCR Ki 4.53 DRUG MATRIX
Melanocortin receptor 5 GPCR Ki 4.60 DRUG MATRIX
Melanocortin receptor 3 GPCR Ki 4.76 DRUG MATRIX
Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Enzyme IC50 4.52 DRUG MATRIX
Solute carrier family 22 member 2 Transporter IC50 4.06 WOMBAT-PK
Emopamil-binding protein-like Enzyme Ki 8.55 CHEMBL
Anti-estrogen binding site (AEBS) Enzyme Kd 9 CHEMBL
Androgen receptor Transcription factor Ki 4.82 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 6.42 DRUG MATRIX
Progesterone receptor Transcription factor Ki 5.59 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 4.66 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 4.92 CHEMBL
C-8 sterol isomerase Enzyme Ki 5.82 CHEMBL
Sodium/potassium-transporting ATPase subunit alpha-2 Ion channel IC50 4.81 DRUG MATRIX
Transcriptional activator protein luxR Unclassified IC50 4.40 CHEMBL

External reference:

IDSource
4019939 VUID
N0000148024 NUI
D00966 KEGG_DRUG
54965-24-1 SECONDARY_CAS_RN
4018462 VANDF
4019939 VANDF
C0039286 UMLSCUI
CHEBI:41774 CHEBI
CTX PDB_CHEM_ID
CHEMBL83 ChEMBL_ID
DB00675 DRUGBANK_ID
CHEMBL786 ChEMBL_ID
D013629 MESH_DESCRIPTOR_UI
2733526 PUBCHEM_CID
1016 IUPHAR_LIGAND_ID
3299 INN_ID
094ZI81Y45 UNII
10324 RXNORM
2281 MMSL
4270 MMSL
5540 MMSL
d00381 MMSL
002670 NDDF
004826 NDDF
373345002 SNOMEDCT_US
41395001 SNOMEDCT_US
75959001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0378-0144 TABLET 10 mg ORAL ANDA 26 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0378-0274 TABLET 20 mg ORAL ANDA 26 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2472 TABLET 10 mg ORAL ANDA 25 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2472 TABLET 10 mg ORAL ANDA 25 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2473 TABLET 20 mg ORAL ANDA 25 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 0591-2473 TABLET 20 mg ORAL ANDA 25 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0485 TABLET 10 mg ORAL ANDA 25 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0942 TABLET 20 mg ORAL ANDA 25 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51407-439 TABLET, FILM COATED 10 mg ORAL ANDA 28 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51407-439 TABLET, FILM COATED 10 mg ORAL ANDA 28 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51407-440 TABLET, FILM COATED 20 mg ORAL ANDA 28 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51407-440 TABLET, FILM COATED 20 mg ORAL ANDA 28 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51862-446 TABLET, FILM COATED 20 mg ORAL ANDA 26 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51862-447 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51862-642 TABLET, FILM COATED 10 mg ORAL ANDA 28 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51862-642 TABLET, FILM COATED 10 mg ORAL ANDA 28 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51862-643 TABLET, FILM COATED 20 mg ORAL ANDA 28 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 51862-643 TABLET, FILM COATED 20 mg ORAL ANDA 28 sections
SOLTAMOX HUMAN PRESCRIPTION DRUG LABEL 1 51862-682 LIQUID 20 mg ORAL NDA 33 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 54868-3004 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 54868-4287 TABLET, FILM COATED 20 mg ORAL ANDA 26 sections
Tamoxifen Citrate Human Prescription Drug Label 1 59651-299 TABLET, FILM COATED 10 mg ORAL ANDA 24 sections
Tamoxifen Citrate Human Prescription Drug Label 1 59651-300 TABLET, FILM COATED 20 mg ORAL ANDA 24 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 60429-909 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 60429-909 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 60429-910 TABLET, FILM COATED 20 mg ORAL ANDA 26 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 60429-910 TABLET, FILM COATED 20 mg ORAL ANDA 26 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 63187-976 TABLET 20 mg ORAL ANDA 25 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 63739-143 TABLET, FILM COATED 10 mg ORAL ANDA 28 sections
Tamoxifen Citrate HUMAN PRESCRIPTION DRUG LABEL 1 63739-269 TABLET, FILM COATED 10 mg ORAL ANDA 26 sections